HIV-1 gp41 Antibody (A00020.01): sc-81011
- HIV-1 gp41 Antibody (A00020.01) is a mouse monoclonal IgG1, cited in 1 publications, provided at 100 µg/ml
- raised against recombinant gp41 of HIV-1 origin
- recommended for detection of gp41 envelope glycoprotein of HIV-1 origin by ELISA
- At present, we have not yet completed the identification of the preferred secondary detection reagent(s) for HIV-1 gp41 Antibody (A00020.01). This work is in progress.
QUICK LINKS
SEE ALSO...
HIV-1 gp41 Antibody (A00020.01) is a mouse monoclonal IgG1 antibody that specifically detects HIV-1 gp41 by enzyme-linked immunosorbent assay (ELISA). HIV-1 gp41 monoclonal antibody (A00020.01) recognizes a crucial glyco-envelope protein involved in the viral life cycle, particularly in viral envelope fusion with host cell membrane for viral entry into target cells. This fusion process enables virus infection of immune cells, leading to HIV infection progression and eventual development of acquired immune deficiency syndrome (AIDS). Anti-HIV-1 gp41 antibody (A00020.01) targets a protein containing a hydrophobic fusion peptide that facilitates viral and cellular membrane merging, critical for viral genome delivery into host cells. Understanding HIV-1 gp41′s function and structure aids therapeutic strategy development and vaccine design for immune response against this viral component. HIV-1 gp41 monoclonal antibody (A00020.01) serves as a valuable research tool for studying HIV-1 pathogenesis and viral infection immune responses.
Alexa Fluor® is a trademark of Molecular Probes Inc., OR., USA
LI-COR® and Odyssey® are registered trademarks of LI-COR Biosciences
HIV-1 gp41 Antibody (A00020.01) References:
- Identification of the HIV-1 gp41 core-binding motif in the scaffolding domain of caveolin-1. | Huang, JH., et al. 2007. J Biol Chem. 282: 6143-52. PMID: 17197700
- Asymmetric deactivation of HIV-1 gp41 following fusion inhibitor binding. | Kahle, KM., et al. 2009. PLoS Pathog. 5: e1000674. PMID: 19956769
- Nonneutralizing HIV-1 gp41 envelope cluster II human monoclonal antibodies show polyreactivity for binding to phospholipids and protein autoantigens. | Dennison, SM., et al. 2011. J Virol. 85: 1340-7. PMID: 21106741
- HIV-1 gp41 ectodomain enhances Cryptococcus neoformans binding to human brain microvascular endothelial cells via gp41 core-induced membrane activities. | Huang, SH., et al. 2011. Biochem J. 438: 457-66. PMID: 21668410
- Discovery of small molecule fusion inhibitors targeting HIV-1 gp41. | Zhou, G. and Chu, S. 2013. Curr Pharm Des. 19: 1818-26. PMID: 23092284
- Inhibition of HIV-1 gp41 expression with hammerhead ribozymes. | Fedoruk-Wyszomirska, A., et al. 2015. Biochem J. 471: 53-66. PMID: 26209679
- HIV-1 gp41-targeting fusion inhibitory peptides enhance the gp120-targeting protein-mediated inactivation of HIV-1 virions. | Qi, Q., et al. 2017. Emerg Microbes Infect. 6: e59. PMID: 28634358
- HIV-1 gp41 Residues Modulate CD4-Induced Conformational Changes in the Envelope Glycoprotein and Evolution of a Relaxed Conformation of gp120. | Keller, PW., et al. 2018. J Virol. 92: PMID: 29875245
- Concentration-Dependent Structural Transition of the HIV-1 gp41 MPER Peptide into α-Helical Trimers. | Chiliveri, SC., et al. 2021. Angew Chem Int Ed Engl. 60: 166-170. PMID: 32916024
- The SARS CoV-2 spike directed non-neutralizing polyclonal antibodies cross-react with Human immunodeficiency virus (HIV-1) gp41. | Perween, R., et al. 2021. Int Immunopharmacol. 101: 108187. PMID: 34649114
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
HIV-1 gp41 Antibody (A00020.01) | sc-81011 | 100 µg/ml | $322.00 |